BRIEF published on 11/26/2025 at 00:51, 8 months 15 days ago CureVac annonce les résultats de son assemblée générale extraordinaire Assemblée Générale Extraordinaire BioNTech Approbation Des Actionnaires CureVac Fusion Légale
BRIEF published on 11/26/2025 at 00:51, 8 months 15 days ago CureVac Announces Results of Extraordinary General Meeting BioNTech Extraordinary General Meeting CureVac Shareholders Approval Legal Merger
PRESS RELEASE published on 11/26/2025 at 00:46, 8 months 15 days ago CureVac Announces Voting Results of Extraordinary General Meeting CureVac announces approval of BioNTech's exchange offer for outstanding shares at Extraordinary General Meeting with over 99.16% approval rate BioNTech MRNA Technology Exchange Offer CureVac EGM Voting Results
BRIEF published on 11/24/2025 at 13:15, 8 months 17 days ago CureVac publie ses résultats financiers du troisième trimestre et des neuf premiers mois de 2025 Performance Financière CureVac Technologie De L'ARNm Résultats Du Troisième Trimestre 2025 Fusion BioNTech
BRIEF published on 11/24/2025 at 13:15, 8 months 17 days ago CureVac Reports Q3 and Nine-Month Financial Results for 2025 Financial Performance MRNA Technology CureVac Q3 2025 Results BioNTech Merger
PRESS RELEASE published on 11/24/2025 at 13:10, 8 months 17 days ago CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates CureVac announces financial results for Q3 and first nine months of 2025, BioNTech transaction progresses, EMA clearance received for cancer therapy CVHNLC sqNSCLC Financial Results Cancer Therapy CureVac BioNTech Transaction EMA Clearance
BRIEF published on 08/15/2025 at 13:32, 11 months 27 days ago CureVac Reports Q2 and H1 2025 Financial Results; Announces Key Developments Financial Results MRNA Technology CureVac Patent Resolution BioNTech Acquisition
BRIEF published on 08/15/2025 at 13:32, 11 months 27 days ago CureVac publie ses résultats financiers du deuxième trimestre et du premier semestre 2025 et annonce des développements clés Résultats Financiers CureVac Technologie De L'ARNm Résolution De Brevet Acquisition De BioNTech
PRESS RELEASE published on 08/15/2025 at 13:27, 11 months 27 days ago CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac announces Q2 2025 financial results, business updates & agreement with BioNTech for transformative mRNA treatments. Strong cash position Financial Results BioNTech CureVac MRNA Q2 2025
BRIEF published on 08/08/2025 at 02:20, 1 year ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
Published on 08/11/2026 at 14:30, 37 minutes ago AIAI Holdings' Constellation Network Launches Dôr Retail Intelligence: Transformational AI-Powered Retail Intelligence
Published on 08/11/2026 at 14:00, 1 hour 7 minutes ago First Canadian Graphite Signs Agreement with Groupe Nipi, in Collaboration with BBA, for its Preliminary Environmental Study at Lac Guéret Sud
Published on 08/11/2026 at 14:00, 1 hour 7 minutes ago First Canadian Graphite conclut une entente avec le Groupe Nipi en collaboration avec la firme BBA pour une étude environnementale préliminaire au Lac Guéret Sud
Published on 08/11/2026 at 13:30, 1 hour 37 minutes ago Nextech3D.ai CEO Evan Gappelberg Purchases 250,000 Shares in Open Market
Published on 08/11/2026 at 14:45, 22 minutes ago The NAGA Group: SMC Research confirms “Speculative Buy” rating and price target of EUR 10.00
Published on 08/11/2026 at 14:05, 1 hour 2 minutes ago zvoove Acquires Pixi, the AI Agent to Automate Administrative Work for Staffing Agencies
Published on 08/11/2026 at 13:40, 1 hour 26 minutes ago Julius Meinl Living completes the sale of EUR 7.6 million of 2024 / 2029 notes
Published on 08/11/2026 at 13:05, 2 hours 2 minutes ago Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
Published on 08/11/2026 at 13:00, 2 hours 7 minutes ago Original-Research: Aspermont Ltd. (von GBC AG): Buy
Published on 08/10/2026 at 18:00, 21 hours 7 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 21 hours 7 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 21 hours 22 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 1 day 3 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
